The ASC4START phase 3 trial aimed to assess asciminib vs. nilotinib tolerability in newly diagnosed Ph+ CML-CP adults. The primary endpoint was to determine the TTDAE. Patients are being treated along with multiple ongoing screenings. An anticipated 2–4.5 years for study completion. Asciminib, the pioneering BCR-ABL1 inhibitor designed to selectively target the ABL […]...
Trusted insights straight to your inbox and get the latest updates from OncWeekly
Advertisement
Introduction Immune checkpoint inhibitors (ICIs) can elicit anticancer immune responses, but predictive biomarkers are needed. We measured programmed death ligand 1 (PD-L1) expression in organs and lymph nodes using 18F-BMS-986192 positron emission tomography (PET)-imaging and looked …
Introduction Treatment with the immune checkpoint inhibitor anti-programmed cell death protein-1 (PD-1) often causes immune-related adverse events (irAEs). Since irAEs resemble autoimmune diseases, autoantibodies might play a role and could potentially be used to identify patients …
Background How distinct methods of host preconditioning impact the efficacy of adoptively transferred antitumor T helper cells is unknown. Methods CD4+ T cells with a transgenic T-cell receptor that recognize tyrosinase-related peptide (TRP)-1 melanoma antigen were polarized to …
Chimeric antigen receptor (CAR) T-cell therapy has emerged as a transformative treatment for various hematological malignancies. Still, its remarkable efficacy is accompanied by unique adverse events that must be carefully managed. This comprehensive literature review …
